Multicenter study to transplant hepatitis C-infected kidneys (MYTHIC): an open-label study of combined glecaprevir and pibrentasvir to treat recipients of transplanted kidneys from deceased donors with hepatitis C virus infection | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Multicenter study to transplant hepatitis C-infected kidneys (MYTHIC): an open-label study of combined glecaprevir and pibrentasvir to treat recipients of transplanted kidneys from deceased donors with hepatitis C virus infection

Sise ME, Goldberg DS, Kort JJ, et al. Multicenter study to transplant hepatitis C-infected kidneys (MYTHIC): an open-label study of combined glecaprevir and pibrentasvir to treat recipients of transplanted kidneys from deceased donors with hepatitis C virus infection. J Am Soc Nephrol. 2020;31(11):2678-2687.

Publication Type:

Journal Article

Authors:

Sise, ME; Goldberg, DS; Kort, JJ; et, al

Source:

J Am Soc Nephrol, Volume 31, Issue 11, p.2678-2687 (2020)

Cited On:

Treatment of HCV-Uninfected Transplant Recipients Receiving Organs From HCV-Viremic Donors

Export Citation:

RIS Format

Top